Press Releases
RayzeBio’s new hub revolutionizes cancer treatment with next-gen RPTs
That’s how quickly RayzeBio radiopharmaceutical therapies, or RPTs, can be delivered after release from a new centrally located Bristol Myers…
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ in Elderly
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will…
Sironax grants Novartis exclusive option to acquire its brain delivery platform
Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a…
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for…
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO and OSENVELT
Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively, are commercially…
NICE approves new drug for advanced bowel cancer patients in England and Wales
We're delighted to see the news that the National Institute for Health and Care Excellence (NICE) has approved the use…
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
Sandoz, the global leader in generic and biosimilar medicines, today announced the start of construction for a new, state-of-the-art biosimilars…
Fresenius Expands Biosimilars Portfolio With the Availability of Their Denosumab Biosimilars in the U.S.
Fresenius announced today that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence®(1) (denosumab-bnht) and Bomyntra®(2) (denosumab-bnht)…
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA)…
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement…